Effects of Yogurt Enriched with Konjac Glucomannan and Inulin on Insulin Sensitivity, Glycemic Control, Lipid
Mohammad Jafar Dehzad1, Ali Raja1, Zahra Moghdani1
1Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz 7153675500, Iran.
Abstract:
Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder that requires effective dietary strategies for management. In this randomized, double-blind, placebo-controlled clinical trial, the effects of low-fat yogurt enriched with konjac glucomannan (KGM) and inulin on glycemic control, lipid profiles, anthropometric indices, and oxidative stress were investigated in patients with T2DM. Eighty participants were randomly assigned to consume either 150 g of yogurt enriched with 1.5 g of KGM and 1.5 g of inulin (n=40) or plain low-fat yogurt (n=40) daily for 8 weeks. The primary outcomes were fasting blood glucose and fasting insulin levels, insulin sensitivity indices [homeostasis model assessment for insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI)], and glycated hemoglobin. Secondary outcomes included lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride (TG)], anthropometric indices (weight, body mass index, fat mass, skeletal muscle, and waist circumference), and oxidative stress markers. Compared to control group, the intervention significantly improved fasting insulin levels (-1.85 µIU/mL, P=0.042), HOMA-IR (-0.89, P=0.029), and QUICKI (0.11, P=0.032). Lipid profile analysis revealed reductions in TC (-18.51 mg/dL, P=0.049) and TG levels (-15.0 mg/dL, P=0.041). These findings suggest that daily consumption of yogurt fortified with KGM and inulin significantly enhances insulin sensitivity and lipid profiles in patients with T2DM over an 8-week period. This dietary intervention shows promise as a complementary strategy for T2DM management. Further studies are needed to assess the long-term outcomes, optimize doses, and elucidate the underlying mechanisms of this intervention.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides


